Citations

Clear

4799 citation(s) found for "Yu, Jennifer".

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report
Ahn, Kwang Woo , Hu, Zhen‐Huan , Volpe, Virginia O. , Antin, Joseph H. , Sorror, Mohamed L. , Press, Oliver W. , Pidala, Joseph, Negrin, Robert S., Uberti, Joseph P., Agura, Edward, Nash, Richard A. , Mehta, Jayesh, Forman, Stephen J. , Langston, Amelia , Hale, Gregory A., Marks, David I. , Ganguly, Sid, Reshef, Ran , Hildebrandt, Gerhard , Inamoto, Yoshihiro , Cahn, Jean‐Yves, Solh, Melhem , Kharfan‐Dabaja, Mohamed A. , Saad, Ayman , Aljurf, Mahmoud , Schouten, Harry C. , Hill, Brian T. , Pawarode, Attaphol , Kindwall‐Keller, Tamila L. , Saba, Nakhle S. , Copelan, Edward A. , Nathan, Sunita , Beitinjaneh, Amer , Černý, Jan , Wirk, Baldeep , Olsson, Richard F. , Bashey, Asad, Sobecks, Ronald , Alyea, Edwin P. , Saber, Wael , Brown, Jennifer R. , Hogan, William, Kharfan-Dabaja, Mohamed A., Saad, Ayman , Press, Oliver , Olsson, Richard F , Reshef, Ran , Kim, Haesook T. , Davids, Matthew S. , Shadman, Mazyar , Hogan, William J. , Devine, Steven M. , McGuirk, Joseph P. , Giralt, Sergio , Perales, Miguel‐Angel , Battiwalla, Minoo , Gale, Robert Peter , Hamadani, Mehdi , Bacher, Ulrike , Lazarus, Hillard M. , Cahn, Jean‐Yves , Ghosh, Nilanjan , Savani, Bipin N. , Grunwald, Michael R. , Yared, Jean A. , Nishihori, Taiga , Chhabra, Saurabh , Gergis, Usama , Popat, Uday R , Sorror, Mohamed

Mayo Clinic

Clinical Cancer Research | June 28, 2019 | Volume: 25 | Issue: 16 | Pages: 5143-5155

10.1158/1078-0432.ccr-18-3988 | PMID 31253630 Get It

Abstract Purpose: To develop a prognostic model and cytogenetic risk classification for previously treated patients with chronic lymphocytic leukemia (CLL) undergoing reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT). Experimental Design: We performed a retrospective analysis of outcomes of 606 patients with CLL who underwent RIC allogeneic HCT between 2008 and 2014 reported to the Center for International Blood and Marrow Transplant Research. Results: On the basis of multivariable models, disease status, comorbidity index, lymphocyte count, and white blood cell count at HCT were selected for the development of prognostic model. Using the prognostic score, we stratified patients into low-, intermediate-, high-, and very-high-risk [4-year progression-free survival (PFS) 58%, 42%, 33%, and 25%, respectively, P < 0.0001; 4-year overall survival (OS) 70%, 57%, 54%, and 38%, respectively, P < 0.0001]. We also evaluated karyotypic abnormalities together with del(17p) and found that del(17p) or ≥5 abnormalities showed inferior PFS. Using a multivariable model, we classified cytogenetic risk into low, intermediate, and high (P < 0.0001). When the prognostic score and cytogenetic risk were combined, patients with low prognostic score and low cytogenetic risk had prolonged PFS (61% at 4 years) and OS (75% at 4 years). Conclusions: In this large cohort of patients with previously treated CLL who underwent RIC HCT, we developed a robust prognostic scoring system of HCT outcomes and a novel cytogenetic-based risk stratification system. These prognostic models can be used for counseling patients, comparing data across studies, and providing a benchmark for future interventions. For future study, we will further validate these models for patients receiving targeted therapies prior to HCT.
Diarrhoea: interventions, consequences and epidemiology in the intensive care unit (DICE-ICU): a protocol for a prospective multicentre cohort study
Dionne, Joanna C. , Sullivan, Kristen , Takaoka, Alyson, Duan, Erick , Alhazzani, Waleed , Duprey, Matthew S. , Armstrong, David , Thabane, Lehana , Tsang, Jennifer , Jaeschke, Roman , Hamielec, Cindy, Karachi, Tim , Cartin‐Ceba, Rodrigo , Cook, Deborah J, Mbuagbaw, Lawrence , Tsang, Jennifer L Y , Alshahrani, Mohammed Saeed Saad , Thabane, Lehana , Sullivan, Kristen, Devlin, John W. , Moayyedi, Paul , Muscedere, John , Cook, Deborah J, Armstrong, David

Mayo Clinic

BMJ Open | June 27, 2019 | Volume: 9 | Issue: 6 | Pages: e028237

10.1136/bmjopen-2018-028237 | PMID 31248929 Get It

Introduction Diarrhoea is a frequent concern in the intensive care unit (ICU) and is associated with prolonged mechanical ventilation, increased length of ICU stay, skin breakdown and renal dysfunction. However, its prevalence, aetiology and prognosis in the critically ill have been poorly studied. The primary objectives of this study are to determine the incidence, risk factors and consequences of diarrhoea in critically ill adults. The secondary objectives are to estimate the incidence of Clostridium difficile- associated diarrhoea (CDAD) in ICU patients and to validate the Bristol Stool Chart and Bliss Stool Classification System characterising bowel movements in the ICU. Our primary outcome is the incidence of diarrhoea . Our secondary outcomes include: CDAD, ICU and hospital mortality and ICU and hospital length of stay. Methods and analysis This international prospective cohort study will enrol patients over 10 weeks in 12 ICUs in Canada, the USA, Poland and Saudi Arabia. We will include all patients 18 years of age and older who are admitted to the ICU for at least 24 hours and follow them daily until ICU discharge. Our primary outcome is the incidence of diarrhoea based on the WHO definition, during the ICU stay. Our secondary outcomes include: CDAD, ICU and hospital mortality and ICU and hospital length of stay. We will use logistic regression to identify factors associated with diarrhoea (as defined using WHO criteria) and the kappa statistic to measure agreement on diarrhoea rates between the WHO definition and the Bristol Stool Chart and Bliss Stool Classification System. Ethics and dissemination The protocol has been approved by the research ethics board of all participating centres. The diarrhoea interventions, consequences and epidemiology in the intensive care unit (DICE-ICU) study will generate evidence about diarrhoea and its frequency, predisposing factors and consequences, to inform critical care practice and future research. Lay summary Diarrhoea is a frequent clinical problem for hospitalised patients including those who are critically ill in the ICU. Diarrhoea can cause complications such as skin damage, dehydration and kidney problems. It is not clear how common diarrhoea is in the ICU, the factors that cause it or the best way for clinicians to assess it. The DICE-ICU study is an international prospective observational study to examine the frequency, risk factors and outcomes of diarrhoea during critical illness.
How to build a robust provider improvement partnership program to enhance patient experience – A case study
Iyer, Venkat, Prissel, Pamela, Munson, Karee, Eide, Jennifer, Brustad, Rebecca, Kranz, Nickie, Madson, Lukas P., Frase, Beverly, Iyer, Venkat

Mayo Clinic

Patient Experience Journal | June 27, 2019 | Volume: 5 | Issue: 1 | Pages: 126-136

10.35680/2372-0247.1228 Get It

Patient experience is emerging as a key differentiating factor in patients’ choice of healthcare system. Many healthcare organizations are attempting to improve their patient experience by data-driven, patient-centered initiatives. This involves engaging all staff along all the contact points of a patient’s journey in healthcare. Perhaps, the physicians or care providers are most important link in this chain but also the most challenging to engage in improvement efforts. Most healthcare organizations have some training or workshops to educate providers on communication skills and other tools to enhance patient experience. However, there seems to a paucity of a standardized approach or a roadmap to put together a robust physician or care provider coaching or improvement partnership program with patient experience (PX) staff. There seems to be several gaps in this process. The current article attempts to develop broad guidelines and suggest a roadmap to address these gaps. The article also suggests general templates for PX staff to use in conducting these improvement work with providers and suggestions for developing a standard physician observation or shadowing template for consistency. The article has woven several commonly used tools like motivational interviewing, change management (ADKAR model), and several communication tools to suggest a detailed blue print for provider patient experience improvement partnership.
National Association of Medical Examiners Position Paper: Recommendations for the Postmortem Assessment of Suspected Head Trauma in Infants and Young Children
Andrew, Thomas, Gilliland, M.G.F., Matshes, Evan W., Reichard, R. Ross , Gill, James Ritchie , Love, Jennifer

Mayo Clinic

Academic Forensic Pathology | June 26, 2019 | Volume: 4 | Issue: 2 | Pages: 206-213

10.23907/2014.032 Get It

The National Association of Medical Examiners convened a panel to create a position paper for recommendations for the investigation of infant deaths due to inflicted head trauma. The correct certification of both the cause and manner of death is dependent upon an evaluation of all available data including information derived from the investigation, scene, postmortem examination, and ancillary studies. This paper provides recommendations for the forensic pathologist on what constitutes the dataset to be produced during the postmortem examination of infants who have died of, or have apparently died of, inflicted head trauma. Specifically, this paper describes 1) procedures, 2) ancillary laboratory tests, and 3) forms of documentation that are important in the investigation of these deaths. The evaluation and documentation of such infant deaths involves the production of a detail oriented and thoroughly documented examination that is independently reviewable to support the multitude of inquiries that may follow from the public and the criminal justice system.
Loss of succinate dehydrogenase B immunohistochemical expression distinguishes pulmonary chondromas from hamartomas
Chatzopoulos, Kyriakos , Fritchie, Karen , Aubry, Marie‐Christine, Carney, J Aiden, Folpe, Andrew L. , Fritchie, Karen J. , Boland, Jennifer M. , Aubry, Marie-Christine

Mayo Clinic

Histopathology | June 25, 2019 | Volume: 75 | Issue: 6 | Pages: 825-832

10.1111/his.13945 | PMID 31236950 Get It

AimsPulmonary chondromas, which are rare cartilaginous neoplasms that often arise in the setting of Carney triad, are morphologically similar to pulmonary hamartomas, which are much more common. There is evidence that succinate dehydrogenase (SDH) deficiency drives neoplasia in patients with Carney triad, and SDHB immunohistochemistry can be used as a surrogate marker to detect SDH deficiency. The aim of this study was to investigate the utility of SDHB immunohistochemistry in distinguishing pulmonary chondromas from hamartomas.Methods and resultsImmunohistochemistry for SDHB (clone 21A11AE7) was performed on histological sections from six cases of pulmonary chondroma and 33 cases of pulmonary hamartoma. SDHB expression was retained in all 33 pulmonary hamartomas, and lost in the majority of evaluable chondromas (five of six). Of the five patients with chondromas showing SDHB loss, four had definitive Carney triad. Most patients with pulmonary hamartomas were older males with small solitary masses, whereas chondromas often presented as multiple masses in young females.ConclusionLoss of SDHB immunohistochemical expression can be useful for differentiating pulmonary chondromas from hamartomas, and potentially identifying patients with Carney triad.
A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation
Carey, Elizabeth J. , Lai, Jennifer C. , Sonnenday, Christopher J. , Tapper, Elliot B. , Duarte‐Rojo, Andrés , Dunn, Michael A. , Tsien, Cynthia , Kallwitz, Eric R. , Ng, Vicky L. , Bashir, Mustafa R. , Montano-Loza, Aldo J , Lai, Jennifer , Duarte-Rojo, Andres , Tandon, Puneeta , Dasarathy, Srinivasan , Kappus, Matthew R. , Montaño‐Loza, Aldo J.

Mayo Clinic

Hepatology | June 20, 2019 | Volume: 70 | Issue: 5 | Pages: 1816-1829

10.1002/hep.30828 | PMID 31220351 Get It

Loss of muscle mass and function, or sarcopenia, is a common feature of cirrhosis and contributes significantly to morbidity and mortality in this population. Sarcopenia is a main indicator of adverse outcomes in this population, including poor quality of life, hepatic decompensation, mortality in patients with cirrhosis evaluated for liver transplantation (LT), longer hospital and intensive care unit stay, higher incidence of infection following LT, and higher overall health care cost. Although it is clear that muscle mass is an important predictor of LT outcomes, many questions remain, including the best modality for assessing muscle mass, the optimal cut‐off values for sarcopenia, the ideal timing and frequency of muscle mass assessment, and how to best incorporate the concept of sarcopenia into clinical decision making. For these reasons, we assembled a group of experts to form the North American Working Group on Sarcopenia in Liver Transplantation to use evidence from the medical literature to address these outstanding questions regarding sarcopenia in LT. We believe sarcopenia assessment should be considered in all patients with cirrhosis evaluated for liver transplantation. Skeletal muscle index (SMI) assessed by computed tomography constitutes the best‐studied technique for assessing sarcopenia in patients with cirrhosis. Cut‐off values for sarcopenia, defined as SMI < 50 cm 2 /m 2 in male and < 39 cm 2 /m 2 in female patients, constitute the validated definition for sarcopenia in patients with cirrhosis. Conclusion: The management of sarcopenia requires a multipronged approach including nutrition, exercise, and additional pharmacological therapy as deemed necessary. Future studies should evaluate whether recovery of sarcopenia with nutritional management in combination with an exercise program is sustainable as well as how improvement in muscle mass might be associated with improvement in clinical outcomes.
Harmonicity: Behavioral and Neural Evidence for Functionality in Auditory Scene Analysis
Patten, K. Jakob , McBeath, Michael K. , Eschbacher, Jennifer , Baxter, Leslie C. , Baxter, Leslie C.

Mayo Clinic

Auditory Perception & Cognition | June 18, 2019 | Volume: 1 | Issue: 3-4 | Pages: 150-172

10.1080/25742442.2019.1609307 Get It

Utility of the Movement Disorders Society Criteria for Progressive Supranuclear Palsy in Clinical Practice
Ali, Farwa , Botha, Hugo , Whitwell, Jennifer L. , Josephs, Keith A. , Botha, Hugo

Mayo Clinic

Movement Disorders Clinical Practice | June 18, 2019 | Volume: 6 | Issue: 6 | Pages: 436-439

10.1002/mdc3.12807 | PMID 31392243 Get It

ABSTRACTObjectivesWhen the 2017 Movement Disorders Society Criteria for progressive supranuclear palsy is applied, patients may appear to have multiple phenotypes. The maximum allocation extinction rules were developed to provide a consistent method for applying the criteria and reaching a single diagnostic label. In this study, we apply both to a neuropathologic cohort of progressive supranuclear palsy and other parkinsonian conditions.MethodsAn autopsy cohort of 54 patients with progressive supranuclear palsy and 56 patients with other neuropathologic diseases was selected. Clinical data were retrospectively abstracted, and the diagnostic criteria for progressive supranuclear palsy were applied. All possible phenotypes applicable were listed and maximum allocation extinction rules were applied to assess reduction in the number of phenotypes ascribed per patient.ResultsIn the progressive supranuclear palsy group, 52 patients met the criteria for multiple phenotypes, with an average of 7 phenotypes per patient. In the nonprogressive supranuclear palsy group, all 56 patients had features of more than one phenotype, up to 3 per patient. After application of maximum allocation extinction rules, the majority of the patients in both groups had a single predominant phenotype. Freezing of gait, supranuclear gaze palsy, and frontal behavioral syndrome were more common in the progressive supranuclear palsy group.ConclusionsThe diagnostic criteria for progressive supranuclear palsy identify many clinical features, thereby leading to assignment of multiple phenotypes per patient. We demonstrate that the maximum allocation extinction rules can effectively lead to a single consensus phenotype, maintaining a uniform diagnostic label for clinical and research applications.
Safety and compatibility of smart device heart rhythm monitoring in patients with cardiovascular implantable electronic devices
Abudan, Anas, Isath, Ameesh , Ryan, J. , Henrich, Mark, Dugan, Jennifer , Ladewig, Dorothy J., Friedman, Paul A. , Abudan, Anas A , Ryan, James D , Henrich, Mark J, Dugan, Jennifer L, Dillon, John J, Friedman, Paul A , Attia, Zachi I. , Dillon, John

Mayo Clinic

Journal of Cardiovascular Electrophysiology | June 13, 2019 | Volume: 30 | Issue: 9 | Pages: 1602-1609

10.1111/jce.14024 | PMID 31190453 Get It

AbstractIntroductionEmerging medical technology has allowed for monitoring of heart rhythm abnormalities using smartphone compatible devices. The safety and utility of such devices have not been established in patients with cardiac implantable electronic devices (CIEDs). We sought to assess the safety and compatibility of the Food and Drug Administration‐approved AliveCor Kardia device in patients with CIEDs.Methods and ResultsWe prospectively recruited patients with CIED for a Kardia recording during their routine device interrogation. A recording was obtained in paced and nonpaced states. Adverse clinical events were noted at the time of recording. Electrograms (EGMs) from the cardiac device were obtained at the time of recording to assess for any electromagnetic interference (EMI) introduced by Kardia. Recordings were analyzed for quality and given a score of 3 (interpretable rhythm, no noise), 2 (interpretable rhythm, significant noise) or 1 (uninterpretable). A total of 251 patients were recruited (59% with a pacemaker and 41% with ICD). There were no adverse clinical events noted at the time of recording and no changes to CIED settings. Review of all EGMs revealed no EMI introduced by Kardia. Recordings were correctly interpreted in 90% of paced recordings (183 had a score of 3, 43 of 2, and 25 of 1) and 94.7% of nonpaced recordings (147 of 3, 15 of 2, and 9 of 1).ConclusionThe AliveCor Kardia device has an excellent safety profile when used in conjunction with most CIEDs. The quality of recordings was preserved in this population. The device, therefore, can be considered for heart rhythm monitoring in patients with CIEDs.
ADDITION OF LENALIDOMIDE TO R‐CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG‐ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R‐CHOP
Nowakowski, Grzegorz S. , Macon, Rita E., King, Rebecca L. , Wagner‐Johnston, Nina, Wade, James L. , Nagargoje, Gauri G., Reynolds, Christopher M. , Cohen, Jonathon B. , Amengual, Jennifer E. , Richards, Kristy L. , Little, Richard F. , Leonard, John P. , Friedberg, Jonathan W. , Kostakoglu, Lale , Kahl, Bradley, Hong, Fangxin , Scott, David W. , Habermann, Thomas M. , Casulo, Carla , Khan, Niloufer , Witzig, Thomas E.

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 37-38

10.1002/hon.6_2629 Get It